Applied to 1,891 participants from the Alzheimer’s Disease Neuroimaging Initiative, the model accurately predicts key AD biomarkers—including amyloid-β, tau, neurodegeneration, and cognition—outperforming clinical and neuroimaging benchmarks. The gene discussed is MAPT; the disease is Alzheimer disease.